155 related articles for article (PubMed ID: 11316866)
21. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model.
Andoh TF; Lindsley J; Franceschini N; Bennett WM
Transplantation; 1996 Aug; 62(3):311-6. PubMed ID: 8779675
[TBL] [Abstract][Full Text] [Related]
22. An underlying role for hepatobiliary dysfunction in cyclosporine A nephrotoxicity.
Aleo MD; Doshna CM; Fritz CA
Toxicol Appl Pharmacol; 2008 Jul; 230(1):126-34. PubMed ID: 18407308
[TBL] [Abstract][Full Text] [Related]
23. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506.
Andoh TF; Burdmann EA; Fransechini N; Houghton DC; Bennett WM
Kidney Int; 1996 Oct; 50(4):1110-7. PubMed ID: 8887267
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach.
Sumethkul V; Tankee P; Chalermsanyakorn P; Jirasiritham S
Transplant Proc; 2010 Dec; 42(10):4040-2. PubMed ID: 21168621
[TBL] [Abstract][Full Text] [Related]
25. Beneficial effects of pentoxifylline on cyclosporine-induced nephrotoxicity.
Kaputlu I; Sadan G; Karayalçin B; Boz A
Clin Exp Pharmacol Physiol; 1997 May; 24(5):365-9. PubMed ID: 9143789
[TBL] [Abstract][Full Text] [Related]
26. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.
Trotter JF; Wachs ME; Trouillot TE; Bak T; Kugelmas M; Kam I; Everson G
Liver Transpl; 2001 May; 7(5):401-8. PubMed ID: 11349259
[TBL] [Abstract][Full Text] [Related]
27. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
28. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
[TBL] [Abstract][Full Text] [Related]
29. Impact of reduced nephron mass on cyclosporine- and/or sirolimus-induced nephrotoxicity.
Fernandes I; Zhang Y; Qi Y; Wang ME; Podder H; Lisik W; Knight R; Kahan BD; Stepkowski SM
Transplantation; 2009 Dec; 88(12):1323-31. PubMed ID: 20029328
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood.
Serkova NJ; Christians U
Ther Drug Monit; 2005 Dec; 27(6):733-7. PubMed ID: 16404806
[TBL] [Abstract][Full Text] [Related]
31. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
Russ G; Segoloni G; Oberbauer R; Legendre C; Mota A; Eris J; Grinyó JM; Friend P; Lawen J; Hartmann A; Schena FP; Lelong M; Burke JT; Neylan JF;
Transplantation; 2005 Nov; 80(9):1204-11. PubMed ID: 16314787
[TBL] [Abstract][Full Text] [Related]
32. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic and nephroprotective benefits of using Schisandra chinensis extracts in a cyclosporine A-based immune-suppressive regime.
Lai Q; Wei J; Mahmoodurrahman M; Zhang C; Quan S; Li T; Yu Y
Drug Des Devel Ther; 2015; 9():4997-5018. PubMed ID: 26355803
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of conversion from cyclosporine to rapamycin on testicular function and morphology in a rat transplantation model.
He Z; Qiu J; Li J; Zhao D; Chen G; Chen L
Transplant Proc; 2013 Mar; 45(2):763-9. PubMed ID: 23498818
[TBL] [Abstract][Full Text] [Related]
35. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model.
Fryer J; Yatscoff RW; Pascoe EA; Thliveris J
Transplantation; 1993 Feb; 55(2):340-5. PubMed ID: 8434385
[TBL] [Abstract][Full Text] [Related]
36. The effect of silibinin on experimental cyclosporine nephrotoxicity.
Zima T; Kameníková L; Janebová M; Buchar E; Crkovská J; Tesar V
Ren Fail; 1998 May; 20(3):471-9. PubMed ID: 9606735
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Casarini DE; Moreira S; Tedesco-Silva H; Medina-Pestana JO
Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
[TBL] [Abstract][Full Text] [Related]
38. Chronic cyclosporine nephrotoxicity: a pig model.
Cibulskyte D; Kaalund H; Pedersen M; Hørlyck A; Marcussen N; Hansen HE; Madsen M; Mortensen J
Transplant Proc; 2005 Oct; 37(8):3298-301. PubMed ID: 16298579
[TBL] [Abstract][Full Text] [Related]
39. Rapamycin preserves renal function compared with cyclosporine A after ischemia/reperfusion injury.
Inman SR; Davis NA; Olson KM; Lukaszek VA; McKinley MR; Seminerio JL
Urology; 2003 Oct; 62(4):750-4. PubMed ID: 14550466
[TBL] [Abstract][Full Text] [Related]
40. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
Baboolal K
Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
